Navigation Links
PROLOR Biotech Announces Presentation of Data on Its Long-Acting Clotting Factors at World Federation of Hemophilia World Congress
Date:7/10/2012

mmercial products, including any long-acting versions of human growth hormone, erythropoietin, interferon beta, GLP-1 and other products; that the long-acting products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; that the actual dollar amount of any grants from Israel's Office of the Chief Scientist is uncertain and is subject to policy changes of the Israeli government, and that such grants may be insufficient to assist with product development; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the CTP platform technology could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties.  In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in PROLOR's filings with the Securities and Exchange Commission.  The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required u
'/>"/>
SOURCE PROLOR Biotech, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Data From Phase II Trial of Prolor Biotechs Long-acting Human Growth Hormone Presented at Endo 2012
2. GenWay Biotech Launches New Cardiovascular Diagnostic Blood Test at American Heart Association Scientific Sessions 2011
3. Puma Biotechnology Announces Completion of Private Placement
4. Animal Biotechnology - Technologies, Markets and Companies
5. AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug
6. The European Union Signs Grant Contract to Fund a 2 Million Euro Biotechnology Research Project Led by Hadassah College Jerusalem
7. Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765
8. Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium
9. Metamark Genetics Signs Collaboration Agreement on Novel Therapeutic Targets with Janssen Biotech
10. SuperNova Diagnostics® to Present at Biotech Showcase™ 2012 During JP Morgan Healthcare Conference January 9 - 12
11. Saladax Biomedical, Inc. to Present at Biotech Showcase™ 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... were treated with a statin in the hospital after ... to survive than those who were not, according to ... This study was conducted by the same researchers who ... improve survival in victims of ischemic stroke., Ischemic stroke ... blood vessel that blocks blood from reaching areas of ...
(Date:9/22/2014)... Research and Markets ( ... "Global Biotechnology Reagents Market 2014-2018" report ... Biotechnology reagents are chemical compounds or ... detect and examine another substance to provide a ... to prepare, collect, and examine specimens from the ...
(Date:9/22/2014)... (CTCs) in a mouse model of pancreatic cancer identified ... CTCs, including significant differences from the primary tumor that ... In their study reported in the Sept. 25 issue ... General Hospital (MGH) Cancer Center identified several different classes ... prove to be targets for improved treatment of the ...
(Date:9/22/2014)... Researchers have discovered a way to create a highly ... graphene sheets. The imperfections have unique electronic properties that ... to absorbed gas molecules by 300 times. , The ... Nature Communications . , Amin Salehi- Khojin, asst ... with Mohammad Asadi, graduate student and Bijandra Kumar, post ...
Breaking Biology Technology:Statin use during hospitalization for hemorrhagic stroke associated with improved survival 2Global Biotechnology Reagents Market 2014-2018: Key Vendors are Agilent, BD Biosciences, Bio-Rad, F. Hoffmann-La Roche, Sigma-Aldrich and Thermo Fisher 2Global Biotechnology Reagents Market 2014-2018: Key Vendors are Agilent, BD Biosciences, Bio-Rad, F. Hoffmann-La Roche, Sigma-Aldrich and Thermo Fisher 3Massachusetts General study reveals gene expression patterns in pancreatic CTCs 2Massachusetts General study reveals gene expression patterns in pancreatic CTCs 3Graphene imperfections key to creating hypersensitive 'electronic nose' 2
... of investigational sustained follicle stimulant achieves similar efficacy to ... week period in Phase III Study , , ... SGP ) today announced results from the Phase III ... corifollitropin alfa, first in the class of sustained follicle ...
... a subsidiary of Eisai Corporation of North America, announced ... express and develop therapeutic monoclonal antibodies for the potential ... , , Under the terms of the agreement, ... technology and its expertise to produce and develop a ...
... Pharmaceuticals, Inc. (Nasdaq: PPHM ) today announced that ... device and methods for linking biological agents to labels for ... as In-Line labeling, was developed for the production of radiolabeled ... A study published today in the July 2009 issue ...
Cached Biology Technology:Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa 2Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa 3Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa 4Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa 5Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa 6Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa 7Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa 8Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa 9Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease 2Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease 3Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in The Journal of Nuclear Medicine 2Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in The Journal of Nuclear Medicine 3Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in The Journal of Nuclear Medicine 4
(Date:9/23/2014)... their own "antifreeze" proteins to survive in the ... effect, researchers funded by the National Science Foundation ... inside their bodies resist melting even when temperatures ... be an undesirable consequence of the evolution of ... of Oregon doctoral student Paul Cziko, who led ...
(Date:9/23/2014)... multidisciplinary team at the University of Wisconsin-Madison and the ... affordable way to screen for neural toxins, helping flag ... Institutes of Health (NIH) announced today that the UW-Madison ... to continue the promising work as part of the ... receive approximately $7 million over the three-year project. ...
(Date:9/23/2014)... (PHILADELPHIA) Researchers have encountered variants or isoforms in ... accidental byproducts. A recent study, published in the journal ... called isomiRs have abundances that depend on geographic subpopulations ... a given miRNA may not be the one typically ... that microRNA isoforms are much more common than we ...
Breaking Biology News(10 mins):Antifreeze proteins in Antarctic fish prevent both freezing and melting 2Antifreeze proteins in Antarctic fish prevent both freezing and melting 3UW-Madison team developing 'tissue chip' to screen neurological toxins 2UW-Madison team developing 'tissue chip' to screen neurological toxins 3Slight alterations in microRNA sequences hold more information than previously thought 2Slight alterations in microRNA sequences hold more information than previously thought 3
... at St. Jude Children's Research Hospital have discovered how a ... effects ranging from learning and memory capabilities to glucose production ... called CREB, is a transcription factor—a molecule that binds to ... gene to make the specific protein for which it codes. ...
... provides the most compelling evidence to-date that some dinosaurs ... del Campo track site in Spain's Cameros Basin, contains ... a non-avian therapod dinosaur. , A team led ... La Rioja, Spain, discovered the prints in an area ...
... guys that help bacterial pathogens do their job of infecting ... essence, they knock down the front door of resistance and ... University of California, San Diego (UCSD) School of Medicine have ... YpkA, one of several effectors of the bacteria Yersinia – ...
Cached Biology News:St. Jude study shows genes play an unexpected role in their own activation 2Definitive evidence found of a swimming dinosaur 2How plague-causing bacteria disarm host defense 2
Request Info...
Size & Applications: 100 ul (2 mM). Recommend to use at 1000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.) Storage Temp.: -20C Shelf Life: 6-12 month...
in vitro Translation, Accessory Products...
... Origami host strains are K-12 derivatives ... reductase (trxB) and glutathione reductase (gor) genes, ... the cytoplasm. Studies have shown that expression ... than in another host even though overall ...
Biology Products: